Dkn-01 (Not yet branded)
Other Medications
Description
DKN-01 is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein in the treatment of colorectal cancer. This targeted therapy works by blocking DKK1, a key inhibitor of the Wnt signaling pathway that plays a crucial role in tumor growth and metastasis. DKN-01 has been evaluated in Phase 2 clinical trials specifically for patients with colorectal cancer, representing a novel approach to targeting the Wnt pathway in this malignancy.
Mechanism of Action
DKN-01 binds specifically to the DKK1 protein, preventing it from inhibiting the canonical Wnt signaling pathway. By blocking DKK1, the antibody allows for restoration of normal Wnt signaling, which can suppress tumor growth and enhance the tumor microenvironment's ability to respond to other treatments. This mechanism represents a unique approach to cancer therapy by targeting a pathway regulator rather than growth factors or their receptors directly.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.